Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Rani Therapeutics Holdings (RANI)
NASDAQ:RANI
Holding RANI?
Track your performance easily
Earnings Data
Report Date
Mar 19, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.27Last Year’s EPS
-0.27Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 16, 2021
|% Change Since: -46.96%
|Next Earnings Date:Sep 13, 2021
Earnings Call Sentiment|Positive
The earnings call highlighted significant achievements in clinical trials, partnerships, and market potential, particularly in the obesity sector, while also acknowledging financial challenges and plans for raising additional capital.Company Guidance
During the Rani Therapeutics Q4 2023 earnings call, the management provided guidance on several fronts, focusing primarily on their clinical and financial progress. They highlighted the successful completion of a Phase I trial for RT-111, an orally administered ustekinumab biosimilar, which demonstrated high bioavailability and no serious adverse events. The company is optimistic about the commercial potential of RT-111, given that STELARA, the injectable form, achieved sales of approximately $7 billion in the United States and $10.9 billion globally in 2023. Additionally, Rani's financial position was addressed, with cash, cash equivalents, and marketable securities totaling $48.5 million as of December 31, 2023, expected to fund operations into 2025. The company's research and development expenses for the year were $39.6 million, while general and administrative expenses amounted to $26.5 million. Rani also discussed potential capital-raising strategies, including equity offerings and non-dilutive licensing fees, to support future operations.Positive Phase I Results for RT-111
Rani Therapeutics announced positive results for their Phase I trial of RT-111, an orally administered ustekinumab biosimilar, achieving high bioavailability in humans and being well tolerated with no serious adverse events.
Expansion of Partnership with Celltrion
Rani Therapeutics expanded its partnership with Celltrion to include an adalimumab biosimilar, with Celltrion holding the right of first negotiation to acquire commercial rights after Phase I studies.
Preclinical Success with RaniPill HC
Rani announced preclinical success with RaniPill HC for oral delivery of Humira, achieving delivery in all subjects and progress in high-capacity pill development.
Obesity Market Potential
Rani revealed preclinical data on incretin triagonists for obesity, showing rapid weight loss in animal studies, and highlighted the potential impact in the $100 billion obesity market.
Financial Position and Cost Management
Rani reported cash equivalents of $48.5 million as of December 31, 2023, with sufficient funds to operate into 2025, and highlighted effective cost management despite limited capital.
---
RANI Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
RANI Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 14, 2024 | $2.47 | $2.35 | -4.86% |
| Aug 06, 2024 | $2.50 | $2.43 | -2.80% |
| May 06, 2024 | $7.56 | $7.46 | -1.32% |
| Mar 20, 2024 | $3.57 | $3.60 | +0.84% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Rani Therapeutics Holdings (RANI) report earnings?
Rani Therapeutics Holdings (RANI) is schdueled to report earning on Mar 19, 2025, TBA Not Confirmed.
What is Rani Therapeutics Holdings (RANI) earnings time?
Rani Therapeutics Holdings (RANI) earnings time is at Mar 19, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is RANI EPS forecast?
RANI EPS forecast for the fiscal quarter 2024 (Q4) is -0.27.
---